Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma
- 1 January 1985
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 277 (4) , 323-325
- https://doi.org/10.1007/bf00509089
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Behandlung des Raynaud-Phänomens bei Sklerodermie-Patienten mit einem neuen stabilen Prostacyclin-Derivat*Deutsche Medizinische Wochenschrift (1946), 1984
- EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROMEThe Lancet, 1983
- INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROMEThe Lancet, 1983
- Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis.BMJ, 1982
- Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2)British Journal of Dermatology, 1982
- Prostaglandin E1 therapy for digital ulcers in scleroderma.1982
- Treatment of severe Raynaud's phenomenon with prostaglandin E1Irish Journal of Medical Science, 1981
- Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.BMJ, 1981
- Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.Annals of the Rheumatic Diseases, 1981
- Zur Messung der „spontanen“ Thrombocytenaggregation Plättchenaggregationstest III. MethodikJournal of Molecular Medicine, 1975